Reprieve Cardiovascular last Saturday released results from two trials of its Reprieve-Guided diuretic therapy exploring its use in treating patients hospitalized with acute heart failure, touting that the system allows for safe decongestion.
Results from the trials were presented at the Heart Failure 2019 Congress in Athens, Greece, the Milford, Mass.-based company said.
Reprieve Cardiovascular said that its TARGET-1 and TARGET-2 studies were designed to explore whether its Reprieve-Guided diuretic therapy could achieve safe net volume reduction while significantly alleviating related symptoms in ADHF patients.
“The therapy appears to be safe and quite effective. Reprieve’s automated fluid management technology provided faster, more controlled fluid removal while protecting acute heart failure patients from dangerous drops in blood pressure. It maintained optimal intravascular fluid volume and with it, cardiac output and renal perfusion,” Dr. Piotr Ponikowski of Poland’s Wroclaw Medical University said in a prepared statement.
Patients in the trial served as their own controls, with each undergoing 24 hours of standard diuretic therapy with intravenous furosemide and 24 hours of diuresis with the automated Reprieve-Guided system. Researchers noted that the average urine output increased from 1986 ml to 6284 ml during the 24 hour period, the company said. Improvements in net fluid loss and renal function accompanied by favorable hemodynamic changes were also reports.
Results from the trial showed a significant increase in diuresis, net negative fluid balance, improved kidney function and improvement in clinical symptoms, the company said.
“Reprieve-Guided diuretic therapy is among the first non-pharmacologic advance in treating fluid overload in acute heart failure patients since diuretics were introduced in the 1960s. These results support our continued efforts to evaluate the impact of our therapy on alleviating the pain points clinicians continuously tell us about that complicate care of patients with acute heart failure. These include long hospital stays, high readmission rates, and ultimately poor long-term patient prognosis,” prez & CEO Jim Dillon said in a press release.
Last December, Reprieve Cardiovascular released early study results from the Target II study of its Reprieve-Guided Diuretic Therapy intended to improve fluid management for patients with acute decompensated heart failure, touting improvements in fluid management optimization.